Lung Cancer

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy as treatment to control disease for patients with lung cancer.

The European Commission has expanded the indication for pembrolizumab to include the frontline treatment of patients with metastatic non–small cell lung cancer that expresses PD-L1 on ≥50% of cells and does not harbor an EGFR or ALK mutation.

Lung cancer is the leading cause of cancer-related deaths among men and women in the United States, despite being the second most commonly diagnosed cancer.

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the development of biomarkers in the study of lung cancer.

Bristol-Myers Squibb and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.

Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses combination therapies for patients with lung cancer.

Paul A. Bunn, Jr., MD, professor of Medicine, head of the Division of Medical Oncology at the University of Colorado, discusses combining immunotherapy with chemotherapy and targeted agents in lung cancer.

Alice T. Shaw, MD, PhD, Director of Thoracic Oncology, Massachusetts General Hospital, discusses alectinib as first-line therapy in the treatment of patients with lung cancer.

Lori C. Sakoda, PhD, research scientist at Kaiser Permanente Division of Research and affiliate investigator of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center, discusses her study examining the pleiotropic associations of genetic risk variants for chronic obstructive pulmonary disease (COPD) with lung cancer risk.

Christian Diego Rolfo, MD, PhD, professor and unit coordinator at Antwerp University discusses the European perspective on precision medicine in lung cancer and the importance of clinical trials across different markets.

Immunotherapy is quickly becoming a mainstay in the frontline setting for the treatment of patients with metastatic non–small cell lung cancer.